Dr Sian Klerk Up to now, rapamycin and rapalogs are the most well studied mTOR inhibitors and they are now clinically used as cancer treatments. However, the possibility that inhibition of mTORC1 with these drugs might lead to Akt upregulation and outgrowth of more aggressive lesions is a concern.

Rapamycin and mTOR kinase inhibitors - PMC (nih.gov)

Dr Sian Klerk We "know" that cancers likely start 20 - 40 years earlier, so while good that only skin / canker response early with Rapa is a plus, but I always assume there is chance anything new may have "unknown" consequences.  In economics one talks of known knowns, & unknown knowns.

Spasov I have not searched yet, but that article is from 2008, & far more learned since.  But removing senescent cells, SAPS, & clearing out junk, is likely to permit immune system better chance to counter / contain cancer, which it had been doing for decades.   Cancer is always present, but after age 50, & esp 60, immune system no longer can contain it.  Senolytics incl Rapa more likely to help, rather than hurt.